Agency says unproven claims about CBD products could lead consumers to delay medical care
WEDNESDAY, July 24, 2019 (HealthDay News) — A warning letter has been issued to Massachusetts-based Curaleaf Inc. for illegally selling unapproved cannabidiol (CBD) products online with unproven claims that the products treat cancer, Alzheimer disease, opioid withdrawal, pain, and other health problems, the U.S. Food and Drug Administration says.
Other than one prescription drug to treat rare, severe forms of epilepsy, the FDA has not approved any other CBD products, according to the agency.
It also noted that there is limited information for other CBD products being marketed to consumers and that they have not been evaluated for potential harm.
The FDA said that unproven claims about CBD products could lead consumers to delay important medical care, such as proper diagnosis and treatment.
ED Visits, Hospitalizations for Alcohol, Cannabis Vary by Age 
Cannabis Legalization Linked to More Heart-Related Hospitalizations 
Nearly 1 in 10 Older Adults Used Cannabis in the Past Year 
2016 to 2024 Saw Increase in Patients Using Medical Cannabis 
Research Challenges Fusion for Lumbar Degenerative Spondylolisthesis 
Ultrasound-Guided Hydrodissection Yields Improvements in Carpal Tunnel 
Financial Incentives Boost Tobacco Abstinence in Underserved Adults 
Physical Therapist-Supervised Exercise Improves Outcomes After ACL Reconstruction 
